(Q22252405)

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Comparison of plasma tissue factor levels in unstable and stable angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in pri

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

New options in the treatment of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Endothelial cell function and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Effect of atorvastatin and pravastatin on serum C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Serum neopterin and activity of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Increased serum neopterin: a marker of coronary artery disease activity in women

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Increased plasma concentrations of interleukin-18 in acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Soluble CD40L: risk prediction after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Perturbation of the T-Cell Repertoire in Patients With Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Direct proinflammatory effect of C-reactive protein on human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Circulating cell adhesion molecules and death in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Monocyte chemoattractant protein-1 in human atheromatous plaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021

C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2005.05.086

7 January 2021